Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Traws Pharma Inc TRAW

Healthcare
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a... see more

Recent & Breaking News (NDAQ:TRAW)

The Growing Demand for Cancer Treatment is Raising Immunotherapy Dependence

PR Newswire August 31, 2018

Onconova Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference in New York City

GlobeNewswire August 28, 2018

Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes (MDS) to South America with Pint Pharma

GlobeNewswire August 21, 2018

Onconova Therapeutics Reports Business Highlights and Financial Results for Second Quarter 2018

GlobeNewswire August 14, 2018

Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2018 Financial Results

GlobeNewswire August 7, 2018

Onconova Therapeutics Announces Promotion for Steven M. Fruchtman, M.D.

GlobeNewswire June 21, 2018

Onconova Therapeutics Announces Presentation at the 23rd Congress of the European Hematology Association

GlobeNewswire June 7, 2018

Onconova Therapeutics, Inc. to Present at the 8th Annual LD Micro Invitational

Accesswire May 29, 2018

Onconova Therapeutics, Inc. Reports Business Highlights and Financial Results for First Quarter 2018

GlobeNewswire May 15, 2018

The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Benzinga.com  May 13, 2018

Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2018 Financial Results

GlobeNewswire May 9, 2018

Onconova Therapeutics to Present at the Disruptive Growth and Healthcare Conference on May 8th, 2018

GlobeNewswire May 3, 2018

Onconova Therapeutics Announces Closing of $28.75 Million Upsized Underwritten Public Offering

GlobeNewswire May 1, 2018

Benzinga's Daily Biotech Pulse: Intra-cellular Moves On Poster Presentation, Earnings Beats From Vertex, Exact Sciences

Benzinga.com  April 27, 2018

Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting

GlobeNewswire April 19, 2018

Onconova Therapeutics to Present Updates at Two Investor Conferences in October

GlobeNewswire October 10, 2017

Mid-Afternoon Market Update: Cleantech Solutions Gains After Exclusivity Agreement For Potential Takeover Of Inspirit Studio; 22nd Century Group Shares Drop

Benzinga.com  October 9, 2017

Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric RASopathies on Wednesday, October 11, in New York City

GlobeNewswire October 4, 2017

Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates

GlobeNewswire September 21, 2017

Onconova Therapeutics to Participate in Two Investor Conferences in September

GlobeNewswire September 5, 2017